PHASE 2/3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF ALVR105 (VIRALYM-M) COMPARED TO PLACEBO FOR THE PREVENTION OF ADV, BKV, CMV, EBV, HHV-6, AND JCV INFECTION AND/OR DISEASE, IN HIGH-RISK PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

Registry ID

P-105-202

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ALLOVIR, INC

Start date

2023-06-30

Completion date

2024-01-31

Last update

2022-07-06

Conditions

• HEMATOPOIETIC STEM CELL TRANSPLANT

Related clinical trials

• PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE TREATMENT OF PATIENTS WITH VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
• PLATELET TRANSFUSIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION - THE PATH PHASE III TRIAL
• NOVEL PULMONARY FUNCTION MEASURES FOR DIAGNOSIS OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN.
• A RANDOMIZED PILOT TRIAL COMPARING ANTI-THYMOCYTE GLOBULIN (ATG) WITH ATG PLUS POST TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR PROPHYLAXIS AGAINST ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE (GVHD) IN MATCHED DONOR HEMATOPOIETIC CELL TRANSPLANTS (HCT)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE IN SUBJECTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
• RANDOMIZED CONTROLLED TRIAL OF OLANZAPINE FOR THE CONTROL OF CHEMOTHERAPY-INDUCED VOMITING IN CHILDREN RECEIVING CHEMOTHERAPY FOR HEMATOPOIETIC STEM CELL TRANSPLANT CONDITIONING

View on source registry